Delayed endovascular surgery in patients with acute ST-segment elevation myocardial infarction due to massive culprit arterial thrombosis in the prevention of slow/no-reflow phenomenon

Aim. To assess whether delayed coronary artery stenting (CAS) can reduce the slow/no-reflow incidence in patients with ST-segment elevation myocardial infarction (STEMI) and massive thrombosis (TTG ≥3) of the infarct-related coronary artery (IRCA) compared with immediate CAS within primary PCI.

Material and methods. Out of 3651 primary PCIs performed for acute STEMI in the period from January 2016 to May 2020 at the Mytishchi City Clinical Hospital, the retrospective analysis included 105 patients with massive IRCA thrombosis (TTG ≥3). The patients were divided into two groups: first group (n=55) — delayed CAS, second group (n=50) — immediate CAS. In the immediate CAS group, the PCI procedure ended with routine stent implantation, and in the delayed CAS group, stent implantation was delayed for at least 5 days.

Results. In the delayed CAS group in comparison with immediate one, the slow/no-reflow phenomenon developed much less frequently in the form of a significant increase in the prevalence of TIMI 3 flow, better myocardial perfusion of myocardial blush grade (MBG) 2-3 (81,8 vs 64%; odds ratio (OR) 2,53; p=0,039) and ST segment resolution ≥70% (87,3% vs 58%; OR 4,97; p=0,001).

Conclusion. Delayed CAS in patients with STEMI with massive thrombosis (TTG ≥3) of IRCA reduces the risk of slow/no-reflow phenomenon and can be considered as a possible alternative treatment vs immediate CAS, provided that stable coronary flow is restored before TIMI 3.

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx637.

2. Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of no-reflow after PCI in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010;3(1):27-33. doi:10.1161/CIRCINTERVENTIONS.109.896225.

3. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-Year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55(21):2383-9. doi:10.1016/j.jacc.2009.12.054.

4. Kotani J, Nanto S, Mintz G, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002;106(13):1672-7. doi:10.1161/01.cir.0000030189.27175.4e.

5. Okamura A, Ito H, Iwakura K, et al. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device. J Am Coll Cardiol. 2005;45(2):212-5. doi:10.1016/j.jacc.2004.09.062.

6. XiaoY, FuX, WangY, et al. Effects of different strategies on high thrombus burden in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary catheterization. Coron Artery Dis. 2019;30(8):555-63. doi:10.1097/MCA.0000000000000743.

7. Kelbaek H, Terkelsen CJ, HelqvistS, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol. 2008;51(9):899-905. doi:10.1016/j.jacc.2007.10.047.

8. Wald DS, Bestwick JP. Preventive percutaneous coronary intervention and aspiration thrombectomy-updates in the management of ST-elevation myocardial infarction. J Thorac Dis. 2016;8(8):1908-12. doi:10.21037/jtd.2016.07.73.

9. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;42(1):1-6. doi:10.1016/s0735-1097(03)00566-7.

10. Kelbaek H, Hofsten DE, Kober L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet. 2016;387(10034):2199-206. doi:10.1016/S0140-6736(16)30072-1.

11. Ke D, Zhong W, Fan L, et al. Delayed versus immediate stenting for the treatment of ST-elevation acute myocardial infarction with a high thrombus burden. Coron Artery Dis. 2012;23(7):497-506. doi:10.1097/MCA.0b013e328358a5ad.

12. Carrick D, Oldroyd KG, McEntegart M, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. 2014;63(20):2088-98. doi:10.1016/j.jacc.2014.02.530.

13. Ganyukov VI. Deferred stent implantation in infarct related coronary artery in patients with ST-segment elevation myocardial infarction. Endovaskulyarnaya Khirurgiya (Russian Journal of Endovascular Surgery). 2017;4(1):18-25. (In Russ.)

14. Azarov AV, Semitko SP, Glezer MG, et al. The results of delayed endovascular intervention in ST elevation acute myocardial infarction due to thrombotic occlusion of coronary artery. Cardiovascular Therapy and Prevention. 2017;16(1):40-5. (In Russ.)

15. Braunwald E, Sabatine MS. The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. J Thorac Cardiovasc Surg. 2012;144(4):762-70. doi:10.1016/j.jtcvs.2012.07.001.

16. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879-88. doi:10.1161/01.cir.93.5.879.

17. Van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blushgrade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97(23):2302-6. doi:10.1161/01.cir.97.23.2302.

18. Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103(21):2550-4. doi:10.1161/01.cir.103.21.2550.

19. Vlaar PJ, Svilaas T, vanderHorst IC, et al. Cardiac death and re-infarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet. 2008;371(9628):1915-20. doi:10.1016/S0140-6736(08)60833-8.

20. Ndrepepa G, Mehilli J, Schulz S, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;52(7):512-7. doi:10.1016/j.jacc.2008.05.009.

21. Isaaz K, Gerbay A. Deferred stenting in acute ST elevation myocardial infarction. Lancet. 2016;388(10052):1371. doi:10.1016/S0140-6736(16)31739-1.

22. Isaaz K, Robin C, Cerisier A, et al. A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coron Artery Dis. 2006;17(3):261-9. doi:10.1097/00019501-200605000-00010.

23. Carol A, Bernet M, Curos A, et al. Thrombus age, clinical presentation, and reperfusion grade in myocardial infarction. Cardiovasc Pathol. 2014;23(3):126-30. doi:10.1016/j.carpath.2014.01.007.

24. Vranckx P, Campo G, Anselmi M, et al. Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention. 2012;8(1):71-8. doi:10.4244/EIJV8I1A12.